Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT03941730
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
5 participants
INTERVENTIONAL
2019-08-28
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
NCT01385280
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers
NCT02238808
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
NCT00573755
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT05150652
Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer
NCT00303615
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the anti-tumor activity of estradiol in patients with locally advanced or metastatic triple negative breast cancer (TNBC) that expresses ERbeta (\> 25% moderate or strong nuclear staining).
SECONDARY OBJECTIVES:
I. To examine the safety profile of estradiol when administered at a dose of 2 mg three times daily (TID) to women with locally advanced or metastatic TNBC that expresses ERbeta.
II. To examine the changes in phosphorylated (phospho)-ERbeta, cystatins 1, 2, 4 and 5, phospho-Smad2/3 and Ki-67 in tumor biopsies taken before and after the first cycle of treatment.
EXPLORATORY OBJECTIVES:
I. To examine changes in plasma estradiol, serum cytokine and cystatin levels before/after 1 cycle of estradiol.
II. Analyze the global gene expression profiles of paired biopsies prior to and following 1 cycle of therapy.
III. To develop patient derived xenografts (PDX) that are ERalpha negative, HER2 negative and ERbeta positive (Mayo only).
IV. To examine changes in the relative abundance of circulating immune cell populations after the first cycle of treatment and whether these changes differ with respect to whether the patient is still on treatment after 6 cycles of treatment or not.
OUTLINE:
Patients receive estradiol orally (PO) TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tissue biopsy at the end of cycle 1, collection of blood samples on day 1 of cycle 1 (C1D1), at the end of cycle 1, and at the end of treatment. In addition, patients undergo computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scans at baseline, at the end of cycles 2, 4, and 6, and then every 8 weeks until disease progression.
After completion of study treatment, patients are followed up annually for 5 years from study registration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (estradiol)
Patients receive estradiol PO TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tissue biopsy at the end of cycle 1, collection of blood samples on C1D1, at the end of cycle 1, and at the end of treatment. In addition, patients undergo CT, MRI, or PET scans at baseline, at the end of cycles 2, 4, and 6, and then every 8 weeks until disease progression.
Biopsy
Undergo tissue biopsy
Computed Tomography
Undergo CT
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET
Therapeutic Estradiol
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biopsy
Undergo tissue biopsy
Computed Tomography
Undergo CT
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET
Therapeutic Estradiol
Given PO
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PRE-SCREENING CRITERIA (STEP 0): History of locally advanced or metastatic breast cancer that is ERalpha negative or low (\< 1% nuclear staining) and HER2 negative.
* Note: HER2 negative disease per 2018 American Society of Clinical Oncology/College of American of Pathologists (ASCO/CAP) guidelines, one of the following must apply:
* 0 or 1+ by immunohistochemistry (IHC) and not amplified by in situ hybridization (ISH);
* 0 or 1+ by IHC and ISH not done;
* 2+ by IHC and ISH results are: \< 6.0 HER2 signals/cell with HER2/CEP17 ratio \< 2.0;
* IHC not done and not amplified by ISH.
* PRE-SCREENING CRITERIA (STEP 0): =\< 3 prior chemotherapy regimens for treatment of metastatic breast cancer.
* Note: Prior use of monoclonal antibodies targeting PD1, PDL1 is allowed (if administered as monotherapy it is not counted as a chemotherapy regimen).
* PRE-SCREENING CRITERIA (STEP 0): Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* PRE-SCREENING CRITERIA (STEP 0): Willing to submit a biopsy specimen from locally recurrent or metastatic site (or primary if metastatic site not available) of breast cancer for ERbeta staining to Mayo Clinic Anatomic Pathology.
* PRE-SCREENING CRITERIA (STEP 0): No prior history of metastatic ERalpha positive breast cancer (\>= 1%)
* PRE-REGISTRATION CRITERIA (STEP 1): Presence of moderate or strong nuclear ERbeta staining in \> 25% of cells in specimen submitted during Pre-Screening Step.
* PRE-REGISTRATION CRITERIA (STEP 1): For patients who did not have a biopsy or lacking ERalpha, progesterone receptor (PR), and HER2 results from a locally advanced or metastatic site performed =\< 12 months prior to Pre-Registration: Willing to undergo a standard of care biopsy of locally recurrent or metastatic breast cancer for ERalpha, PR, and HER2 as well as additional research cores.
* PRE-REGISTRATION CRITERIA (STEP 1): Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria that will be assessed using imaging-based evaluations.
* Note: The tumor lesion biopsied during the pre-registration period is not considered measurable disease nor a target lesion.
* PRE-REGISTRATION CRITERIA (STEP 1): If history of brain metastases must meet the following criteria:
* Patients with a history of brain metastases are eligible only if they are asymptomatic and have stable disease for \>= 3 months, including \< 28 days of prior to pre-registration.
* Not receiving steroids for brain metastases.
* PRE-REGISTRATION CRITERIA (STEP 1): ECOG performance status 0 or 1.
* PRE-REGISTRATION CRITERIA (STEP 1): =\< 3 prior chemotherapy regimens for treatment of metastatic breast cancer.
* NOTE: Prior use of monoclonal antibodies targeting PD1, PDL1 is allowed.
* PRE-REGISTRATION CRITERIA (STEP 1): Women must be postmenopausal.
* NOTE: Postmenopausal status is verified by:
* Prior bilateral surgical oophorectomy, or
* Age \>= 60 years, or
* Age \< 60 years with no menses for \> 1 year with estradiol levels within postmenopausal range, according to institutional standard.
* PRE-REGISTRATION CRITERIA (STEP 1): Able to swallow oral medications.
* PRE-REGISTRATION CRITERIA (STEP 1): Willingness to stop use of strong inducers or inhibitors of CYP3A4 prior to registration.
* NOTE: Use of strong inducers or inhibitors is allowed during pre-registration as long as patient will complete course prior to registration.
* REGISTRATION CRITERIA (STEP 2): For patents who had a biopsy taken from a metastatic site =\< 12 months prior to Pre-Registration: Confirmation from the local lab that the tumor from this biopsy was ERalpha negative (\< 1% nuclear staining) and HER2 negative
* REGISTRATION CRITERIA (STEP 2): For patients who underwent a pre-registration biopsy: Histologic confirmation from local lab that tumor is ERalpha negative (\< 1% nuclear staining), and HER2 negative
* REGISTRATION CRITERIA (STEP 2): Hemoglobin \>= 8 g/dL (=\< 14 days prior to registration).
* REGISTRATION CRITERIA (STEP 2): Platelet count \>= 75,000/mm\^3 (=\< 14 days prior to registration).
* REGISTRATION CRITERIA (STEP 2): Creatinine =\< 1.5 x upper limit of normal (ULN) (=\< 14 days prior to registration).
* REGISTRATION CRITERIA (STEP 2): Total bilirubin =\< 1.5 x ULN (=\< 14 days prior to registration).
* REGISTRATION CRITERIA (STEP 2): Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) =\< 2.5 x ULN (=\< 14 days prior to registration).
* For patients with liver metastasis =\< 5 x ULN.
Exclusion Criteria
* Ongoing or active infection.
* Symptomatic congestive heart failure.
* Unstable angina pectoris.
* Uncontrolled symptomatic cardiac arrhythmia.
* Uncontrolled hypertension (defined as blood pressure \> 160/90).
* PRE-REGISTRATION CRITERIA: Deep vein thrombosis / pulmonary embolism (DVT/PE) =\< 12 months prior to pre-registration.
* Note: Patients who are on anticoagulant therapy for maintenance are eligible as long as the DVT and/or PE occurred \> 6 months prior to pre-registration, and there is no evidence for active thrombosis (either DVT or PE).
* PRE-REGISTRATION CRITERIA: Stroke =\< 6 months prior to pre-registration.
* PRE-REGISTRATION CRITERIA: Two or more episodes of DVT and/or PE =\< 5 years prior to pre-registration.
* PRE-REGISTRATION CRITERIA: Abnormal uterine bleeding =\< 6 months prior to pre-registration
* PRE-REGISTRATION CRITERIA: History of coagulopathy.
* PRE-REGISTRATION CRITERIA: Other active second malignancy other than non-melanoma skin cancers within 3 years prior to pre-registration.
* NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for \>= 3 years prior to pre-registration.
* REGISTRATION CRITERIA: None of the following therapies are allowed =\< 14 days prior to registration.
* Chemotherapy.
* Immunotherapy.
* Biologic therapy.
* Hormonal therapy.
* Monoclonal antibodies.
* Anti-HER2 or other "targeted" (e.g. mTOR) therapy.
* Note: Any adverse events derived from these therapies must be =\< grade 2 prior to starting study therapy (exceptions for alopecia).
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew P. Goetz, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
UCSF Medical Center-Mission Bay
San Francisco, California, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Montefiore Medical Center-Einstein Campus
The Bronx, New York, United States
FHCC South Lake Union
Seattle, Washington, United States
University of Washington Medical Center - Montlake
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-02285
Identifier Type: REGISTRY
Identifier Source: secondary_id
MC1831
Identifier Type: OTHER
Identifier Source: secondary_id
18-000734
Identifier Type: OTHER
Identifier Source: secondary_id
TBCRC051
Identifier Type: OTHER
Identifier Source: secondary_id
MC1831
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.